Labcorp to Acquire Select BioReference Health Assets for $722M

Labcorp is acquiring select BioReference Health assets from OPKO Health for $722 million, including clinical and specialized testing operations, more than 80 patient service centers, and the FDA-approved 4Kscore prostate cancer test. The deal expands Labcorp's diagnostics capabilities and access while allowing OPKO to focus on biopharmaceutical development.

This Wire brief sits within Fusion42's coverage of Diagnostics.